CHD is a major cause of morbidity and mortality in women. The incidence of CHD in premenopausal women is low but increases substantially after the menopause, and this difference suggests that endogenous oestrogens are cardioprotective. Observational prospective studies have consistently shown that exogenous oestrogens also lower CHD risk. The biological mechanisms by which endogenous and exogenous oestrogens exert their protective effect are multifactorial, affecting lipids, carbohydrate metabolism, body fat distribution and blood pressure. The prevention of CHD with oestrogen therapy i s therefore aimed both at correction of the traditional risk factors and at direct control of vessel structure and function. The wide international variation in rates of CHD together with the lower mortality in sub-groups of the population suggests that aconsiderable proportion of CHD may be prevented by dietary modification. Since phytooestrogens are structually similar to oestrogen, they have the potential to mimic its effects in vivo. The hypocholesterolaemic effects of soyabean protein (rich in phyto-oestrogen precursors) are well established, but the underlying mechanism and atherogenic potential of these changes are unknown. One isoflavone, genistein, has been shown in vitro to exert effects which may slow the development of atherosclerotic disease. However, further studies are required to determine the dose-related changes induced by phyto-oestrogens on serum lipoproteins, haemostasis and vascular function.
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A. Cassidy and B. Griffm distinguishing risk in women than the more traditional risk factors that have been derived from studies on men (Williams, 1997) . Alterations in serum lipoproteins become evident at the beginning of the menopause, with a progressive increase in total cholesterol and LDL-cholesterol levels. The effects on HDL-cholesterol levels are controversial, but more recent studies suggest that levels do not change significantly as a consequence of the menopause (Stevenson et al. 1993; Bergmann et al. 1997) . This lack of an effect of the menopause on HDL-cholesterol may help to explain why the protective effects of oestrogen extend for sometime beyond the menopause. Some but not all studies have found serum oestradiol levels to be positively associated with HDL-cholesterol levels in post-menopausal women ). The menopause is also accompanied by an increase in serum triacylglycerol (TAG) levels of 7-35 %, independent of age. A recent meta-analysis of seventeen prospective studies identified serum TAG as an independent predictor of CHD risk in women (Hokanson & Austin, 1996) . However, although TAG levels increase after the menopause, they do not reach levels found in older men, but are generally closer to levels observed in young normolipidaemic men (Cohn ef al. 1988) .
Raised serum lipoprotein (a) (Lp(a); a close structural relative of LDL) has been shown to be an independent risk factor for CHD. Although the prevailing view has been that Lp(a) levels are unaffected by age and gender (levels are primarily genetically determined), more recently Bruschi et al. (1996) demonstrated that surgical menopause causes a sharp rise in plasma Lp(a) levels, with levels returning to baseline values with oestrogen treatment. Given that diets and most conventional drugs have no effect on Lp(a), the ability of oestrogen to decrease the concentration of this lipoprotein by up to 35 % (Shewmon et al. 1994 ) is quite unique. The significant positive association between Lp(a) and follicle-stimulating hormone levels proves that changes in the former are strictly dependent on the hypooestrogenic state induced by oophorectomy, and thus suggest an important role for oestrogens in modulating Lp(a) levels.
The predominance of small dense LDL-cholesterol is emerging as a major determinant of LDL atherogenicity (see Griffin, 1999) . After the menopause, dense LDL-cholesterol particles are present with increasing frequency (Campos et al. 1988) . Since the density of LDL-cholesterol particles is related to TAG content, this may in part explain why plasma TAG have been found to be an independent risk factor for CHD in older post-menopausal women (Castelli, 1986) but not in younger women (Austin, 1988) . Increased TAG may therefore be a marker for increased levels of atherogenic lipoproteins rather than the cause of the increased risk of CHD.
Multiple regression analysis indicates that between 25 and 50 % of the reduction in cardiovascular events in postmenopausal oestrogen users is attributed to effects on lipoprotein metabolism (Soma et al. 1997 ). An additional contribution to risk may arise from the menopause producing unfavourable changes in haemostatic factors, with reports of increases in fibrinogen and factor VII and plasminogen activator inhibitor 1, all of which would tend towards a prothrombotic state (Matthews et al. 1989; Meilahn el al. 1990) . Although fibrinogen may be a predictor of CHD in women, results from the Postmenopausal Estrogefiogestogen Intervention trial suggest that it may not be an independent risk factor, since levels are independently related to other lifestyle and physical characteristics, including age, obesity, HDL, LDL (Stefanick et al. 1995) .
Dysfunction of the arterial endothelium may also underlie the increased risk of CHD observed in post-menopausal women. Endogenous and exogenous oestrogens may exert their cardioprotective effects by direct effects on the vasculature, increasing cardiac output, arterial blood flow velocity and decreasing vascular resistance, and systolic and diastolic blood pressure (Magness & Rosenfield, 1989; Farhat et al. 1996) . At physiological concentrations, oestrogen decreased arterial smooth muscle cell migration and proliferation induced by endothelium injury in a mouse carotid artery model (Sullivan et al. 1995) . Oestrogens have also been shown to exert acute and positive effects on the regulation of the arterial vasoreactivity in ovariectomized rhesus monkeys (Macaca rnulatta; Williams et al. 1992) . These direct effects of oestrogen on the arterial wall are thought to be mediated, at least in part, through classic steroid hormone receptors, the presence of which in premenopausal women has been demonstrated in vascular smooth muscle as well as endothelial cells of coronary arteries (Losordo et al. 1994; Kim-Schulze et al. 1996) . However, to date little is known about the expression, function and distribution of oestrogen receptors (ER) in cardiovascular tissues and organs after the menopause.
Hormone-replacement therapy
The prevention of CHD with oestrogens is aimed both at correction of the traditional set of cardiovascular risk factors and at the direct control of vessel structure and function. Observational prospective studies have consistently shown that exogenous oestrogen therapy lowers risk for CHD Meade & Berra, 1992) . Over thirty observational studies and thirteen case-control studies have examined the effect of hormone-replacement therapy (HRT) on cardiovascular events, and a recent meta-analysis estimated that the reduction in CHD associated with oestrogen is 44 % . Part of this reduced risk in HRT users may be explained by selection bias, since women taking post-menopausal oestrogens tend to be healthier and of higher socio-economic status and, therefore, may have different lifestyles from non-users (BarrettConnor, 1991) .
However, oestrogens clearly do have powerful biological actions that could explain their associated cardioprotective effects (Gerhard & Ganz, 1995) . The most important effects of HRT on lipoprotein metabolism relate to the decrease in LDL and increase in HDL, both by approximately 15 % (Knopp, 1991) . Although this does not explain all the cardioprotective effect of HRT, at present there is no consensus regarding the relative importance of other biochemical indices, although HRT appears to reverse the effect of the menopause on clotting factors (factor VII, plasminogen-activating factor 1 and fibrinogen) and Lp(a) levels, and have favourable effects on LDL subtypes (Soma et al. 1997) . Paradoxically, HRT has been associated with increases in TAG of approximately 25 % (Knopp, 1991) . However, an oestrogen-induced reduction in LDL and reciprocal rise in HDL are likely to oppose the metabolic effects of elevated TAG (see Griffin, 1999) , and thus outweigh the risk associated with the latter (Williams, 1997) .
The observed cardioprotective effects of oestrogen appear to be related to current use and diminish after cessation of treatment (Grodstein et aZ. 1996) . Postmenopausal women are therefore faced with a dilemma; oestrogen use may protect against CHD and osteoporosis but may increase the risks of breast and endometrial cancer Col et al. 1997) . The risk of endometrial cancer is substantially mitigated by the addition of progestins (Beresford et al. 1997) , which according to the 16-year follow-up of the Nurse's Health population study (Grodstein et al. 1996) do not appear to attenuate the cardioprotective effect of post-menopausal oestrogen therapy. Lingering concerns about the potential long-term risks associated with HRT preparations have stimulated interest in the manufacture of selective ER modulators, such as Raloxifene. These tissue selective agents could provide the benefits of oestrogen without the accompanying risk (Walsh et al. 1998) . Raloxifene can produce oestrogen-agonistic effects in some factors (e.g. bone and cholesterol) and oestrogen-antagonistic effects in others (e.g. breast). In a recent randomized parallel-designed study Raloxifene favourably altered biochemical markers of CHD by decreasing LDL, fibrinogen and Lp(a) and increasing HDL2, without raising serum TAG concentrations (Walsh et al. 1998) . In contrast to HRT, Raloxifene had no effect on HDL and plasminogen-activating factor 1 and a lesser effect on HDL2 and Lp(a), but for the most part the direction of the response paralleled that of HRT, although it was not necessarily of the same magnitude. The pattern of response bore a greater similarity to Tamoxifen (the anti-oestrogen drug successfully employed in breast-cancer treatment) than to HRT. This overall similarity between Raloxifene and Tamoxifen may be important, since the changes in risk factors induced by Tamoxifen may be responsible for the observed decrease in CHD mortality in women receiving Tamoxifen (McDonald & Stewart, 1991) .
In view of these studies, randomized trials are clearly required to define the effects of HRT (including different regimens and routes of administration) and other potential drug therapies on risk factors for CHD, and importantly to determine the effects of treatment on clinical outcome. However, searching for an ideal drug therapy should not supersede the need to further investigate the potential importance of dietary modification, given the relatively unexplored potential of dietary phyto-oestrogens in the prevention of CHD. The nutritional importance of a highplant-based diet has already been recognized as potentially important in the prevention of many Western diseases, although the mechanism(s) by which dietary phytooestrogens may prevent CHD has to date not received adequate attention.
Dietary phyto-oestrogens
Phyto-oestrogens are naturally-occurring plant chemicals which are currently receiving considerable attention because they offer potential alternative therapies for a range of hormone-dependent conditions, including cancer prevention, menopausal symptoms, CHD and osteoporosis. The two classes of phyto-oestrogens of particular interest to human health are the isoflavones, present in high concentrations in soyabean products, and the lignans, which are measurable in most fibre-rich foods, but linseed is currently the richest identified source @etchell& Adlercreutz, 1988). These compounds are strikingly similar in chemical composition to oestradiol (Fig. l) Controlled intervention studies in premenopausal women provide direct evidence to suggest that diets containing phyto-oestrogens can produce oestrogenic effects in women of reproductive age (Cassidy et al. 1994 (Cassidy et al. , 1995 . A daily intake of textured vegetable protein containing 45 mg isoflavones modified characteristics of the menstrual cycle of healthy premenopausal women and suppressed the magnitude of the normal mid-cycle surge of folliclestimulating hormone and luteinizing hormone. This effect did not occur with an isoflavone-free soyabean protein, suggesting that the isoflavone fraction exerts this endocrine modifying effect, which occurs at the level of the hypothalamic pituitary-gonadal axis. Effects of soyabean diets on oestrogen-sensitive biochemical markers have also been demonstrated in post-menopausal women, and suggest that phyto-oestrogens can act as a weak oestrogen in postmenopausal women Baird et al. 1995; Murkies et al. 1995; Cassidy et al. 1998) . These compounds therefore have the potential to exert similar effects to those of HRT. This is supported by epidemiological evidence which suggests that the incidence of CHD is lower in Asian countries (where soyabean, a rich source of isoflavones, is a staple) than in Western countries (Lock et al. 1988 ). In addition, a lower mortality of CHD has been observed in vegetarians (Key et al. 1996) , who would consume high levels of phyto-oestrogens, particularly lignans, as a result of their plant-based diet. However, although diets high in plant-based foods appear to protect from CHD, the mechanism for this protective effect and the active constituents present in plant foods have not been elucidated, and to date the antioxidant micronutrients and flavonoids have received most attention (Hertog et al. 1993; Gazioano et al. 1995; Pandey et al. 1995) .
The hypocholesterolaemic effect of soyabean has been recognized from animal studies for almost 100 years (Carroll, 1991) . Animal studies have shown that substituting soyabean protein for casein or other animal proteins causes a reduction in total cholesterol and LDL concentrations (Sirtori et al. 1993) . However, in human subjects the clinical response to soyabean protein in terms of its effects on lipoprotein metabolism have been variable, partly because the effects are highly dependent on the initial serum cholesterol concentrations, but also because the studies conducted used different sources and doses of soyabean products and different study designs. A meta-analysis of thirty-eight intervention studies showed mean reductions in serum total cholesterol of 9.3 %, and LDL of 12.9 % in response to soyabean protein (Anderson et al. 1995) . This study concluded that an intake of 25 g soyabean proteidd would be associated with a 0.45 mmoVl decrease in serum cholesterol levels, and the hypocholesterolaemic effect of soyabean was most marked in subjects with the highest initial serum levels. The effect on HDL was marginal, with a small nonsignificant increase (Anderson et al. 1995) . In addition, a recent cross-sectional study showed a significant inverse relationship between soyabean intake and total cholesterol level in a Japanese population (Nagata et al. 1998) . In our own studies normocholesterolaemic premenopausal women showed a mean reduction of 9.6 % in total cholesterol levels when 60 g soyabean protein was given daily over a 1-month period (Cassidy et al. 1994) . Half this dose resulted in a significant decrease in TAG concentrations (Cassidy et al. 1995) . No randomized cross-over trials have been conducted as yet to examine the effect of phyto-oestrogenrich diets on the spectrum of biochemical markers of lipoprotein metabolism and haemostatic factors in human subjects. However, the few short-term studies that have examined the effects of soyabean on lipoprotein metabolism in post-menopausal women and in men have shown no significant effect (Gooderham et al. 1996; Cassidy et al. 1998) . Furthermore, results from studies using purified isoflavone supplements have not shown any effect on lipids (Nestel et al. 1997; Hogson et al. 1998) , although this lack of effect could be explained by the absence of a food matrix, or by the absence of other components of soyabean which may interact with isoflavones to exert the hypocholesterolaemic effect. Quantitatively, the lignans are more important in relation to the UK diet than isoflavones, as they are present in measurable amounts in many plant foods that are regularly consumed in the normal diet (Cassidy, 1997) . However, only limited information on their biological effects in human subjects is available. A short-term study in which 40 g linseed (the richest identified source of lignans) was fed showed favourable modifications to lipid profiles in postmenopausal women and elderly men (Cassidy et al. 1998) . Since the cholesterol reduction appears to be most effective in hypercholesterolaemic subjects, further studies therefore need to be conducted in these sub-groups to examine the dose-response effects of phyto-oestrogen-rich foods on a wide range of biochemical markers of CHD risk. In particular, the relative importance of lignans needs to be addressed. Arjmandi et al. (1997) showed that both ipriflavone (an isoflavone derivative) and soyabean containing isoflavones effectively prevented the unfavourable changes in serum and liver cholesterol levels associated with oestrogen loss. Studies in non-human primates (rhesus monkeys) also showed that phyto-oestrogen-intact soyabean had favourable effects on plasma lipid and lipoprotein concentrations, reducing LDL-and VLDL-cholesterol concentrations by 30-40 % in both males and females, significantly increasing HDL-cholesterol concentrations for females (15 %) and significantly lowering total serum cholesterol : HDLcholesterol (20 % for males, 50 % for females), one of the most sensitive and discriminating markers of lipid-mediated CHD risk (Anthony et al. 1996) .
Whilst such observations suggest that phyto-oestrogens, like oestrogens, can influence HDL-cholesterol and LDLcholesterol, the underlying mechanism and atherogenic potential of these changes is unknown. In the meta-analysis of soyabean-protein trials Anderson et al. (1995) suggested that the isoflavone content of soyabean may account for up to 60 % of the hypocholesterolaemic effect. This has recently been disputed (Sirtori et al. 1997) , since cholesterol-lowering effects have been observed in clinical studies where soyabean foods low in phyto-oestrogen content have been fed. The beneficial effects on lipid profiles may be only one factor in a series of oestrogenrelated protective responses. Honore et al. (1997) showed that phyto-oestrogens, like steroidal oestrogens, can enhance coronary vascular reactivity in atherosclerotic rhesus monkeys. The direct effects of oestrogens on endothelial cells and angiogenesis are an additional focus of interest (Fotsis et al. 1993; Jaggers et al. 1996) , partly because angiogenesis in vascular walls occurs most commonly in atheromas and adherent thrombi. Fotsis et al. (1993) reported that the urine of healthy human subjects consuming a soyabean-based vegetarian diet contained inhibitors of endothelial cell proliferation, and identified genistein (one of the isoflavone precursors) as the effective compound. In vitro, this isoflavone precursor has been shown to inhibit endothelial cell proliferation, migration and tube formation as well as thrombin formation and platelet activation (Sargeant et al. 1993; Wilcox & Blumenthal, 1995) ; the other phyto-oestrogens (daidzein, equol and enterolactone) were considerably less potent in these effects. If genistein can exert these same effects in vivo, it may slow the development or progression of atherosclerotic disease.
There is great interest in the role of flavonoid-rich diets in reducing cardiovascular disease. However, the relative importance of the phyto-oestrogen components of such diets is still unclear. It has been suggested that some of the protective effects of oestrogens and Tamoxifen in terms of cardiovascular disease and cancer reflect their antioxidant properties and effects on membrane fluidity. Recent work by RuizLarrea et al. (1997) showed that genistein enhanced the resistance of LDL to oxidation in vitro, and was the most potent isoflavone antioxidant.
Summary
The biological mechanisms by which oestrogens and phytooestrogens may confer cardioprotection are multifactorial, acting through serum lipoproteins, haemostasis and vascular function. Whilst the evidence to show that exogenous oestrogen therapy may exert beneficial effects on biochemical markers of CHD risk is very compelling, the effects of HRT and other drug therapies, e.g. Raloxifene, on clinical outcome are unknown because of the lack of large-scale randomized placebo-controlled clinical trials. However, the long-term pursuit of therapeutic strategies toreduce CHD risk in the free-living population may be inappropriate, given the proven metabolic potential of phyto-oestrogens. If these compounds can mimic the effect of HRT, and if even some of their effects in vitro occur in vivo, then these compounds offer a serious alternative and rational approach to the primary prevention of CHD.
